CoChat

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

Open access
Said, Rabih, Hong, David S., Warneke, Carla L., Lee, J. Jack, Wheler, Jennifer J., Janku, Filip, Naing, Aung, Falchook, Gerald S., Fu, Siqing, Piha-Paul, Sarina, Tsimberidou, Apostolia M., Kurzrock, Razelle · 2013 · Oncotarget
Cited by 115

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

// Rabih Said 1,* , David S. Hong 1,* , Carla L. Warneke 2 , J. Jack Lee 2 , Jennifer J. Wheler 1 , Filip Janku 1 , Aung Naing 1 , Gerald S. Falchook 1 , Siqing Fu 1 , Sarina Piha-Paul 1 , Apostolia M. Tsimberidou 1 , Razelle Kurzrock 3 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX 2 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 3 UCSD Moores Cancer Center * Denotes equal contribution Correspondence: David Hong, email: // Keywords : P53 mutations, PTEN loss, bevacizumab, Li-Fraumeni syndrome Received : April 10, 2013 Accepted : May 1, 2013 Published : May 1, 2013 Abstract Background: Mutations in the p53 gene are amongst the most frequent aberrations seen in human cancer. Our objective was to characterize the clinical characteristics associated with p53 mutation in patients with advanced cancer. Methods: We retrospectively reviewed and analyzed the clinical features and response to standard systemic therapy of 145 patients with documented tumor p53 mutational status (mutant-type [ mtp 53 ] vs. wild-type [ wtp 53 ]) referred to the Clinical Center for Targeted Therapy. Results: Sixty-six (45.5%) patients had mtp53. Mutations in p53 occurred more frequently in older patients (p= 0.015) and in Caucasians (p=0.024). The incidence of liver metastases was 69.2% vs. 43%, p=0.002 in mtp53 and wtp53 , respectively. PTEN loss by immunohistochemistry was found more frequently in mtp53 -bearing tumors compared to wtp53 (33.3% vs. 10%, p=0.007). The best progression-free survival (PFS) on standard systemic therapy was significantly longer with bevacizumab-containing regimens as compared to non-bevacizumab containing regimen in patients with mtp53 (median 11.0 [ 95 % CI 5 . 9 - 16 . 0 ], n=22 vs. 4.0 months [ 95 % CI 3 . 6 - 5 . 7 ], n=35, p<0.0001) but not those with wtp53 (median 5.0 [ 95 % CI 2 . 0 - 7 . 6 ] vs. 6.0 [ 95 % CI 4 . 0 - 7 . 5 ] months, p=0.318. The median overall survival from diagnosis in patients with mtp53 and wtp53 was 7.4 [ 95 % CI 6 . 3 - 9 . 8 ] vs. 11.8 [ 95 % CI 2 . 9 - 21 . 5 ] years, respectively (p=0.365). Conclusion: Patients with mtp53 tumors were older at diagnosis, had more incidence of liver metastasis, and more frequent PTEN loss. The best PFS on standard systemic therapy was significantly longer with bevacizumab-containing regimens in patients with mutant p53 tumors but not in those with wtp53 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.974

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

Metadata

Authors
Said, R., Hong, D. S., Warneke, C. L., Lee, J. J., Wheler, J. J., Janku, F., Naing, A., Falchook, G. S., Fu, S., Piha-Paul, S., Tsimberidou, A. M., & Kurzrock, R.
Venue
Oncotarget
Published
2013-05-01
Volume
4
Issue
5
Pages
705-714
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2154171668
Cited by
115
References
7
FWCI
6.01
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.